Sam Brusco, Associate Editor01.08.24
Abbott announced that Tandem Diabetes’ t:slim X2 insulin pump with Control-IQ technology is now integrated with its FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) technology.
Tandem’s pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute to the pump. Minute-to-minute glucose data can be seen on the pump and accompanying t:connect mobile app. t:slim X2 with Dexcom G7 CGM rolled out in December.
The pump’s Control IQ predicts glucose levels 30 minutes into the future, adjusting insulin delivery every five minutes based on CGM readings. Automatic correction boluses—up to one an hour—can be delivered to help prevent hyperglycemia.
“Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the U.S.,” said John Sheridan, president and CEO of Tandem Diabetes Care. “This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.”
The FreeStyle Libre 2 Plus sensor is a modified version of the technology, and was cleared in 2023 by the U.S. Food and Drug Administration (FDA). The CGM has a wear time of 15 days for adults and children and has shown an 8.2% MARD in glucose readings.
“Our FreeStyle Libre portfolio empowers people living with diabetes to have more control over their health and eases the burden of their condition by using a continuous glucose monitoring system with unsurpassed accuracy that is simple, easy and affordable to use,” said Jared Watkin, executive VP of Abbott’s diabetes care business. “Through the integration of Tandem’s t:slim X2 insulin pump with our FreeStyle Libre 2 Plus sensor, people only need two sensors a month, which ensures both a more convenient and more affordable experience.”
Abbott earned an FDA nod for its FreeStyle Libre 3 reader in April 2023.
Tandem’s pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute to the pump. Minute-to-minute glucose data can be seen on the pump and accompanying t:connect mobile app. t:slim X2 with Dexcom G7 CGM rolled out in December.
The pump’s Control IQ predicts glucose levels 30 minutes into the future, adjusting insulin delivery every five minutes based on CGM readings. Automatic correction boluses—up to one an hour—can be delivered to help prevent hyperglycemia.
“Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the U.S.,” said John Sheridan, president and CEO of Tandem Diabetes Care. “This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.”
The FreeStyle Libre 2 Plus sensor is a modified version of the technology, and was cleared in 2023 by the U.S. Food and Drug Administration (FDA). The CGM has a wear time of 15 days for adults and children and has shown an 8.2% MARD in glucose readings.
“Our FreeStyle Libre portfolio empowers people living with diabetes to have more control over their health and eases the burden of their condition by using a continuous glucose monitoring system with unsurpassed accuracy that is simple, easy and affordable to use,” said Jared Watkin, executive VP of Abbott’s diabetes care business. “Through the integration of Tandem’s t:slim X2 insulin pump with our FreeStyle Libre 2 Plus sensor, people only need two sensors a month, which ensures both a more convenient and more affordable experience.”
Abbott earned an FDA nod for its FreeStyle Libre 3 reader in April 2023.